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that anomalous cell survival mechanisms are an essen-
tial component of this process. To this end, we have
recently characterized an in vitro model for the analysis
of the EMT that uses a multicellular, three-dimensional
spheroid cell system (LIM 1863 cells) that reiterates the
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contact provided by the organoid structure is necessary
to maintain viability, and isolated cells in culture undergo
apoptosis (Figure 1A) [10]. However, after the EMT, indi-Summary
vidual cells migrate and survive in the absence of any
cell-cell contact (Figure 1A); this finding indicates thatAberrant cell survival and resistance to apoptosis are
this phenotypic transition results in an escape from thehallmarks of tumor invasion and progression to meta-
constraints of adhesion-dependent survival. Clearly,static disease [1], but the mechanisms involved are
LIM 1863 organoids provide a valuable model for study-poorly understood. The epithelial-mesenchymal tran-
ing the acquisition of survival mechanisms as a functionsition (EMT), a process that facilitates progression to
of carcinoma progression.invasive cancer, provides a superb model for studying
such survival mechanisms. Here, we used a unique
spheroid culture system that recapitulates the struc-
Upregulation of VEGF and Flt-1, but Not KDR,ture of the colonic epithelium and undergoes an EMT in
Accompanies EMT in LIM 1863 Organoidsresponse to cytokine stimulation to study this problem
As an initial approach to studying survival mechanisms[2]. Our data reveal that the EMT results in the in-
employed by the organoids, we used RT-PCR to screencreased expression of both VEGF and Flt-1, a tyrosine
for putative “survival factors” (growth factors, cytokines)kinase VEGF receptor, and that the survival of these
whose expression increases in response to the EMT.cells depends on a VEGF/Flt-1 autocrine pathway. Per-
This screen identified VEGF as a candidate survival fac-turbation of Flt-1 function by either a blocking antibody
tor (Figure 1B). These cells express two isoforms ofor adenoviral expression of soluble Flt-1, which acts
VEGF, VEGF165 and VEGF121, and an increase in mRNAin a dominant-negative fashion, caused massive apo-
for both isoforms after EMT induction was apparent. Toptosis only in cells that underwent EMT. This pathway
obtain a more quantitative assessment of these results,was critical for the survival of other invasive colon
we used real-time quantitative PCR (RQ-PCR) and ob-carcinoma cell lines, and we observed a correlative
served that a greater than 3-fold increase in VEGF mRNAupregulation of Flt-1 expression linked to in vivo hu-
expression occurred in response to the EMT (Figure 1C).man cancer progression. A role for Flt-1 in cell survival
The biological effects of VEGF are mediated by twois unprecedented and has significant implications for
well-characterized phosphotyrosine kinase receptors,Flt-1 function in tumor progression, as well as in other
Flt-1 (fms-like tyrosine kinase; VEGFR-1) and KDR (ki-biological processes, including angiogenesis and de-
nase insert domain-containing receptor; VEGFR-2). Al-velopment.
though structurally related, it appears that these two
receptors have distinct biological activities. KDR, whose
Results and Discussion role in endothelial cell function is defined much better
than that of Flt-1, is the dominant signaling receptor
Given that most human tumors are of epithelial origin, for VEGF-induced mitogenesis and permeability [11, 12]
the epithelial-mesenchymal transition has emerged as because of its strong tyrosine kinase activity. In contrast,
a critical step in carcinoma progression [3–5]. This tran- Flt-1 has weaker tyrosine kinase activity yet exhibits a
sition, which is also essential for normal morphogenetic 10-fold higher affinity for binding VEGF [13]. In fact, the
processes [6–8], results in reduced cell-cell interactions lack of significant signaling responses in endothelia to
and increased motility. Although the molecular mecha- Flt-1, and its log-scale higher affinity for VEGF binding,
nisms underlying the EMT are currently being eluci- have led to the suggestion that this molecule acts as a
dated, little attention has been given to the possibility decoy receptor, capable of being either a positive or
negative regulator of angiogenesis [13, 14], through an
ability to sequester VEGF from signaling through KDR.*Correspondence: rbates@caregroup.harvard.edu
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Figure 1. VEGF Expression Increases after
EMT
(A) Photomicrographs of LIM 1863 colon car-
cinoma cells either in culture as organoids
(left panel, Organoid) or 24 hr after treatment
with TNF-/TGF-, which induces an EMT
(right panel, EMT). Individual cells fail to sur-
vive in the absence of cell-cell contact in or-
ganoid culture; however, they survive and mi-
grate after the EMT (arrows). The scale bar
represents 100 m.
(B) RT-PCR for VEGF was performed on RNA
purified from untreated LIM 1863 organoids
(Org) or cells treated with TNF-/TGF- for 24
hr (EMT). The size of the two VEGF products
(VEGF165 and VEGF121) are 535 and 403 bp,
respectively. As a positive control, integrin
6, which also gives two products based on
alternative splicing (347 and 216 bp), was
used.
(C) VEGF mRNA levels were quantified by us-
ing real-time quantitative PCR (RQ-PCR) in
organoid or EMT cultures of LIM 1863 cells.
The fold change between treatments (3.16-
fold induction after the EMT) is represented
graphically.
Although it was assumed that the two VEGF receptors Autocrine VEGF/Flt-1 Signaling Is Essential
for the Survival of Cells that Have Undergoneare expressed almost exclusively on vascular endothe-
lial cells, recent studies have demonstrated both KDR an EMT
To establish the validity of the VEGF/Flt-1 autocrine sig-and Flt-1 expression in tumor cells, including those de-
rived from pancreatic, prostate, and neuroblastoma naling mechanism, we initially sought to perturb this
interaction by using functionally interfering monoclonalcancers [15–17]. Given this consideration, the possibility
arose that a specific VEGF receptor promoted the sur- antibodies. We allowed the cells to undergo an EMT
and treated them with the anti-VEGF antibody 2C3. Thisvival of LIM 1863 cells that had undergone an EMT. To
assess this possibility, we analyzed these cells for Flt-1 antibody blocks the VEGF/KDR interaction with no effect
on VEGF/Flt-1 activity [20]. As expected, we observedand KDR expression (Figure 2). Interestingly, immu-
noblotting revealed that cells within the organoid struc- no impact on cell survival (data not shown). We repeated
these experiments by using the monoclonal antibodyture expressed a minor, yet detectable, amount of Flt-1
and that its expression increased significantly after in- KM1732, which binds to the VEGF binding region in Flt-1
and specifically interferes with Flt-1-mediated signalingduction of the EMT (Figure 2A). Flow cytometry revealed
a 4-fold increase in Flt-1 surface expression (Figure 2B). [21]. Between 48 and 72 hr after treatment, we consis-
tently observed an almost synchronous rounding up andThis finding was substantiated further by RT-PCR (Fig-
ure 2C), which showed a clear increase in the Flt-1 mes- detachment of cells from the plates. Apoptosis under
these conditions was assessed by annexin V-FITC andsage in post-EMT cells. In contrast, LIM 1863 cells do
not express any KDR, and the EMT does not result in PI staining (Figure 3A). The untreated and control IgG
cells exhibited low levels of annexin positivity and com-an increased expression of this VEGF receptor (Figure
2D). Further, we investigated by RT-PCR whether there parable levels of PI cells. In stark contrast, anti-Flt-1
treatment resulted in significantly higher levels of apo-was upregulation of placental growth factor, the other
potential ligand for Flt-1, and found that message levels ptotic and dead cells, as measured by annexin V/PI
staining and PI cells, respectively. The combined datafor this cytokine were actually repressed significantly
after the transition (data not shown). We and others have indicated that 72 hr after antibody treatment, almost
two-thirds of the cells were dead and over one-third ofpreviously shown that transcriptional regulation of Flt-1
is dependent on the Ets-1 transcription factor [18, 19], those that were alive were apoptotic. The addition of
KM1732 to intact organoid cultures had no discernibleand we observed a concomitant increase in both expres-
sion and activity of this factor as a function of the EMT effect on morphology or survival (data not shown). We
conclude from these data that blocking VEGF binding(see Figure S1 in the Supplemental Data available with
this article online). This finding provides a mechanistic to Flt-1, at the site of the receptor itself, perturbed an
autocrine signaling pathway that promoted cell survival.explanation for EMT-induced Flt-1 receptor expression.
Taken together, our results reveal a potential autocrine Of note, this is the first direct demonstration of a survival
signaling function for the Flt-1 receptor.signaling pathway for cell survival, mediated through a
VEGF/Flt-1 interaction, that is elaborated as a conse- To substantiate this unexpected finding, we next per-
formed a set of experiments with an adenoviral con-quence of the EMT.
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Figure 2. EMT Induces Expression of Flt-1,
but Not KDR
(A) Cell extracts were prepared from intact
organoids (Org) or 24 hr post-TNF-/TGF-
treatment (EMT) and were immunoblotted
with a polyclonal antibody directed against
Flt-1. The relative molecular masses are
shown to the left in kDa. Equal protein loading
was confirmed by tubulin immunoblotting
(not shown).
(B) LIM 1863 organoids were either disaggre-
gated into single cell suspensions (Organoid)
or harvested at 24 hr after induction of the
EMT (EMT), and surface expression of Flt-1
was assessed by flow cytometry. A greater
than 4-fold increase in Flt-1 surface expres-
sion occurs after the EMT.
(C) RT-PCR for Flt-1 was performed on RNA
purified from untreated LIM 1863 organoids
(Org) or post-EMT cells (EMT). The predicted
size of the PCR product is 498 bp. Control
amplification of the neuropilin message con-
firmed equal loading (lower panel).
(D) LIM 1863 organoids were disaggregated
into single cell suspensions or harvested at
24 hr after the EMT induction, and surface
expression of the KDR receptor was as-
sessed by flow cytometry. LIM 1863 cells do
not express KDR protein, nor is the protein
induced after the transition.
struct encoding for a soluble form of Flt-1, the protein to the post-EMT phenotype of LIM 1863, these cells
expressed a high level of Flt-1 on their surface but lackedproduct of which acts in a dominant-negative fashion
any KDR (data not shown). Following adenoviral infec-to the endogenously expressed receptor [22]. Infection
tion with either Ad.LacZ or Ad.sFlt-1, these cells wereof the LIM 1863 cell line with this adenovirus (Ad.sFlt-1)
simply maintained in culture. Strikingly, expression ofresulted in production of the truncated sFlt-1 protein,
sFlt-1 induced a virtually complete loss of cells duewell in excess of the endogenously expressed receptor
to cell death by 48 hr postinfection, a result that wasin organoids (Figure 3B). Expression of sFlt-1, or infec-
confirmed and quantified by annexin V-FITC and PItion with a control adenovirus (Ad.LacZ), had no effect
staining (Figure 3E). In addition, we infected the SW-on organoid cell survival (Figure 3C, upper panel). How-
480 cell line, which also exhibits a poorly differentiatedever, when organoids were induced to undergo EMT,
and invasive phenotype, and observed a similar apo-untreated and Ad.LacZ-infected cells underwent a typi-
ptotic response that was specific for those cells ex-cal conversion. In contrast, the sFlt-1-expressing cells
pressing the soluble form of the receptor (data notunderwent massive cell death as a consequence of the
shown). Moreover, each adenoviral assay using thesetransition (Figure 3C, lower panel). The observation that
three colon carcinoma cell lines was performed in thethe cells were undergoing apoptosis within this shorter
presence of serum (5%), indicating that the autocrinetime frame (24 hr) was confirmed by in situ apoptosis
VEGF/Flt-1 promotion of cell survival is dominant overstaining (Figure 3D). Thus, blocking VEGF binding to
any other soluble growth factor signal. Overall, theseFlt-1 or impacting receptor function in a dominant-nega-
data support the hypothesis that Flt-1-induced survivaltive fashion results in cell death only in posttransitional
protection is characteristic of invasive colon carcinoma.cells. Significantly, these findings define the acquisition
Although there is emerging evidence for tumor-spe-of a self-regulated survival pathway as an essential com-
cific VEGF autocrine signaling [15, 24], the mechanismsponent of the EMT process itself. Clearly, the develop-
involved and consequences of such signaling have re-ment of an inherent ability to suppress apoptosis,
mained elusive. Two recent reports may be of particularthrough autocrine signaling, would play a critical role
relevance to our findings. Firstly, although not tumorin colorectal tumorigenesis and points to the selective
related, Gerber et al. [25] have argued for the existenceadvantages of Flt-1 expression by carcinoma cells.
of an internal or “private” autocrine loop regulated by
VEGF in hematopoietic stem cells, but not in endothelia,
Flt-1 Promotes Survival in Colon Carcinoma that promotes their survival. This internal loop was sen-
Cell Lines sitive to small-molecule inhibitors of VEGF receptor
To ensure that Flt-1-dependent survival was not a cell (both KDR and Flt-1) kinase activity, but a soluble Flt-1-
line-specific response, we examined the SW-837 colon Ig chimera, which acts in a similar dominant-negative
carcinoma cell line because this line was derived from manner to our virally expressed product, had no effect.
a high-stage (stage IV) tumor and therefore is represen- Secondly, the leukemic cell line Molt-4 was shown to
be sensitive to the effects of the anticancer agent aplid-tative of a post-EMT, invasive phenotype [23]. Similar
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Figure 3. Flt-1 Is Essential for the Survival of Cells that Have Undergone an EMT
(A) Following EMT induction, LIM 1863 cells were treated with the function-blocking monoclonal antibody KM1732 (anti-Flt-1), an isotype-
matched control (Control IgG), or medium alone (Untreated) for 72 hr. Apoptosis assays were then performed on these cell populations. The
percentage of annexin V/PI cells (left panels) and PI cells (right panels) are indicated.
(B) Cellular extracts were prepared from untreated LIM 1863 cells () or LIM 1863 cells 24 hr postinfection with Ad.sFlt-1 () and were
immunoblotted with an anti-Flt-1 antibody. The relative molecular masses are shown to the left in kDa. The relative positions of endogenous
receptor (Flt-1) and the virally produced soluble form (sFlt-1) are indicated.
(C) Uninfected (Untreated), control (Ad.LacZ), or soluble Flt-1-infected (Ad.sFlt-1) LIM 1863 cells were prepared. Cells were maintained as
organoids (upper panel) or induced to undergo EMT for 24 hr (lower panel) and were visualized under phase-contrast microscopy. The scale
bar represents 100 m.
(D) Cell populations were prepared as described above, and, after EMT induction, apoptosis was assessed by using a fluorescein in situ
death detection (TUNEL) method. Cells were photographed under fluorescent microscopy (lower panel), and the corresponding phase-contrast
images are shown in the upper panel. The scale bar represents 100 m.
(E) SW-837 colon carcinoma cells were infected with Ad.LacZ or Ad.sFlt-1 adenovirus as indicated, or they were left untreated. After 48 hr in
culture, apoptosis assays were performed. The percentage of annexin V/PI cells (left panels) and PI cells (right panels) are indicated.
ine [26], whose action involves a possible block in auto- tissue showed histologically normal colonic mucosa
(Figure 4A). Flt-1 staining of the same tissue revealedcrine VEGF/Flt-1 signaling necessary to maintain growth
of these cells. Overall, the downstream effectors and strong immunoreactivity in the vascular endothelium
(arrow), muscularis mucosae (arrowhead), and perivas-signaling intermediates specific for Flt-1 signaling re-
main elusive, and our organoid/EMT model provides an cular smooth muscle (Figure 4B). Since Flt-1 is ex-
pressed by these cell types [27, 28], they provided idealattractive new model that can be used to investigate
this problem. internal positive controls. As expected, the normal co-
lonic epithelium did not exhibit any staining for Flt-1. H&
E staining of the corresponding tumor sample showedFlt-1 Expression during Progression of Human
significant cytologic atypia and an invasive growth pat-Colon Carcinoma In Vivo
tern, diagnostic of carcinoma (Figure 4C). In stark con-A key finding of this study is that Flt-1 expression corre-
trast to the normal epithelium, within the tumor, we ob-lates with the progression of human colon cancer, as
served a strong heterogeneous expression of the Flt-1predicted by the spheroid EMT model. In Figure 4, we
receptor by the carcinoma (c) cells themselves that wasprovide the first direct demonstration of Flt-1 protein
similar in intensity to the surrounding smooth muscleexpression for human carcinoma tissue in vivo, as as-
(Figure 4D). The specificity of this staining was high-sessed by immunohistochemistry on matched normal
lighted by the observation that Ft-1 expression withinand carcinoma samples obtained from patients with co-
lon cancer. Hematoxylin-eosin (H&E) staining of control the smooth muscle fibers (sm) was restricted to the
Flt-1 Signals Tumor Cell Survival
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Figure 4. In Vivo Flt-1 Protein Expression in
Human Colon Carcinoma
(A–F) Representative (A and C) H&E or (B and
D) Flt-1 immunohistochemistry in (A and B)
normal colon or (C and D) matched carcinoma
tissue. Flt-1 immunoreactivity in the (B) nor-
mal sample is restricted to the smooth muscle
of the muscularis mucosae (arrowhead), endo-
thelium (arrow), and the perivascular smooth
muscle, (D) whereas the smooth muscle (sm)
and the carcinoma tissue (c) are both positive
in the tumor sample. Flt-1 immunostaining is
shown for a separate carcinoma sample in
(E), with tumor cells infiltrating the stroma
showing high expression of the receptor
(arrows). (F) depicts the corresponding nega-
tive control for the tumor shown in (D). The
scale bars equal 500 M in (A) and (B) and
100 M in (C)–(F).
smooth muscle cells, with the interstitial fibrous tissue lung, and colon-derived tumors [31–35]. In each case,
these studies reported suppression of primary tumorbeing negative. Consistent with the hypothesis that Flt-1
growth and prolonged animal survival based on the abil-expression occurs as a function of tumor progression,
ity of sFlt-1 to block angiogenesis, presumably by antag-an incidental case of adenoma for this particular tumor
onizing VEGF activity and inhibiting vascular formationsample was also found to be negative (data not shown).
and permeability. Thus, antiangiogenic gene therapyFurther, in a separate clinical specimen, high Flt-1 ex-
with soluble Flt-1 is considered to be a potential avenuepression was detected in the more poorly differentiated
for therapeutic exploitation. From a clinical perspective,infiltrating tumor cells (arrows) invading through des-
however, colorectal tumors present a more complexmoplastic stroma (Figure 4E). These data indicate that
paradigm. The high mortality and morbidity of this dis-Flt-1 expression correlates with the progression of colon
ease are due, in part, to the fact that diagnosis of thesecarcinoma. This result is substantiated by a previous
tumors is often a late occurrence, well after the primaryreport that both VEGF and Flt-1 gene expression are
tumor has developed. Surgical resection remains theupregulated, at least at the mRNA level, during the neo-
primary treatment recourse, and effective chemothera-plastic progression of human colonic mucosa [29]. In
peutic options, unfortunately, remain limited. For theseaddition, increased Flt-1 mRNA has been detected in
reasons, it would appear that antiangiogenic therapy,hepatic metastases of human colorectal cancers com-
targeting early tumor development, might be less effec-pared to the surrounding nontumorous liver [30]. The
tive for these types of cancer. However, the data weheterogeneous expression pattern we observed sug-
have presented here suggest that it may be possible togests that groups of cells within a given tumor can
selectively target invading and metastasizing cells, atacquire selectively advantageous phenotypes, presum-
least for colon carcinoma. In this regard, it is interestingably by EMT, that may ultimately confer a more signifi-
to note that one new antiangiogenic agent, known ascant metastatic capacity.
bevacizumab (Avastin, Genentech), is, in fact, showing
considerable therapeutic promise in Phase III clinical
Flt-1 – A Multifunctional Chemotherapeutic Target? trials for colorectal cancer when used in combination
The Flt-1-mediated effects on tumor cell survival that with standard therapy regimes. This humanized anti-
we characterized may have important implications for body binds to VEGF and neutralizes VEGF function by
therapy. Gene transfer of soluble Flt-1 by using adenovi- steric hindrance [36]; therefore, its effects in vivo have
ral delivery systems has been effective in murine models been interpreted as acting via an inherent ability to in-
hibit angiogenesis. However, since these trials are lim-for a number of cancers, including ovarian, pancreatic,
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plastic and macroscopically normal tissue were procured from eachited to patients who have advanced metastatic disease,
specimen and were immediately embedded in OCT embedding me-and in light of the results we are presenting here, it
dium (Tissue-tek) and frozen in liquid nitrogen. Immunohistochemis-is not mutually exclusive that this drug might also
try was performed by using the avidin-biotin complex protocol on
be affecting VEGF-mediated survival pathways in the frozen tissue.
tumor cells.
In summary, the results of this study highlight a novel Supplemental Data
and unexpected function for Flt-1 in promoting aberrant The Supplemental Data demonstrate a correlative increase in the
expression and activity of the Ets-1 transcription factor, which pro-tumor cell survival, and one that appears intimately
vides a mechanistic explanation for the EMT-induced upregulationlinked to the EMT and tumor progression. Additionally, in
of Flt-1, and are available at http://www.current-biology.com/cgi/contrast to KDR, roles for Flt-1 have remained enigmatic,
content/full/13/19/1721/DC1/.even in endothelial cells. Our findings emphasize the fact
that Flt-1 activation can positively regulate essential,
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